Business Wire

TECNOTREE

22.2.2024 11:37:30 CET | Business Wire | Press release

Share
Tecnotree Reports High Revenue Growth Above Global Market Trends, in Q4 and Full Year 2023

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the fourth quarter and full year of 2023. The company delivered record revenue at 78.4 M Euros, outperforming global market trends, with excellent demand for Tecnotree products. Tecnotree experienced the highest-ever order intake at 95.4 M Euros and secured 12 new logos including 3 Tier-1 operators in Scandinavia and North America regions, reflecting an increased demand for digital cloud offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222509053/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Key highlights of the fourth quarter 2023:

  • Net sales increased 10.4% to EUR 22.2 (20.1) million
  • Operating results increased 29.5% to EUR 7.9 (6.1) million
  • The result for the period decreased by 22.5% mainly due to a higher exchange loss of EUR 2.4 (3.1) million
  • Operating Cash flow EUR 4.7 (0.6) million
  • Earnings per share EUR 0.01 (0.01)
  • Order book at the end of the period increased by 16.4% to EUR 80.2 (68.9) million

Key Highlights for the full year 2023:

  • Net sales increased 9.5% to EUR 78.4 (71.6) million
  • Operating results increased 30.2% to EUR 23.8 (18.3) million
  • Result for the period is EUR 11.2 (11.6) million
  • Operating Cash flow EUR 6.2 (6.0) million
  • Earnings per share EUR 0.04 (0.04)

Tecnotree CEO, Padma Ravichander, said, “As we close out the fourth quarter and the full year, I am proud to say that we have surpassed our expectations by delivering record order intake, record revenue, and high profitability. We continued to execute our strategy in 2023 and demonstrated digital leadership thanks to Tecnotree’s competitive product portfolio and its ability to drive outcome-based digital transformations. In 2023, the company increased its investment in AIML competitiveness, which accounted for 15.6% of the total order intake, resulting in AIML revenue exceeding the projected growth for the year.

We have continued to build and transform our culture in 2023 and have consistently showcased our dedication to driving innovation and value for our customers. I would like to express my gratitude to our partners and employees for their commitment to carrying out Tecnotree's vision, together we stand ready to shape the future. Looking ahead, our competitive strength will be the cornerstone of everything we do, as we remain focused on delivering differentiated experiences.”

Significant milestones and business achievements for the year included:

  • Tecnotree celebrated 14 go-lives globally for some of the largest operator groups across various regions, delivering large-scale Digital BSS transformation for customers through the Tecnotree Digital Suite.
  • Gartner recognized Tecnotree in their Market Guide for Customer Experience Management and in another Market Guide for Revenue Monetisation and Management.
  • Tecnotree was recognized as a Finalist in the TM Forum Excellence Awards 2023 for Customer Experience for the implementation of the Tecnotree Digital Stack embedded with AIML to drive business outcomes for MTN
  • Tecnotree was awarded the Diamond Badge for TM Forum Open API Conformance. The certification verifies the successful implementation of Open APIs with conformance to a total of 9 real-world and 59 certified Open APIs. This achievement makes Tecnotree No. 1 on the TM Forum Open API Conformance table.
  • The company was also the Top Vendor for official conformance and certification for TM Forum's Business Process Framework (eTOM) in 2023
  • Tecnotree obtained 20 new patents covering various areas such as Augmented Intelligence, Gen AI, ML Ops, and Data Ops. The patents also include common frameworks and methodologies, utilizing Sensa Low-Code Tooling & Platform and Co-pilots embedded for FTTX, Mobile, and B2B2x Marketplace B/OSS modules.
  • The company was recognized among the top 4 major vendors globally for Autonomous AI and Autonomous Agents Market by Markets and Markets for implementing various types of organic and inorganic growth strategies such as product launches, upgrades, partnerships, M&As, and business expansions by region and by verticals
  • Tecnotree Moments was awarded best Telecom Monetisation Platform by the Dubai Government
  • The company was honoured with two prestigious awards - ‘Best Innovation in Information Technology’ by CMO Asia and 'Best Workplace Diversity Award' by UBS Forums
  • Tecnotree was recognized as a top performing Mid-Cap company by the Nordic Diversity Index, reinforcing our commitment to fostering a diverse and inclusive workplace that drives innovation and empowers every individual within the company

About Tecnotree

Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree leads the way on the TM Forum Open API Conformance with 59 certified Open APIs including 9 real-world open APIs, a testament to the company's commitment to excellence, and continuously striving to deliver differentiated experiences and services to both CSPs and DSPs. Our agile and open-source digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on the Helsinki Nasdaq (TEM1V).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222509053/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye